(Total Views: 630)
Posted On: 01/27/2025 8:59:51 PM
Post# of 153977
Quote:
I haven't ran across any studies looking at FGF21 and CCR5 interaction
There is a mouse study investigating combination therapy of CCR2/CCR5 antagonist and FGF21 analogue which suggested an additive effect.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9224277/
“Until today, we’ve not had the prospect of an effective treatment for compensated cirrhosis due to MASH, which is associated with high rates of short-term morbidity and mortality,” said Mazen Nourredin, M.D., Professor of Medicine and Transplant Hepatologist at Houston Methodist Hospital, and principal investigator for the SYMMETRY study. “Now we have reason to be optimistic about the future potential of EFX as a much-needed treatment for cirrhosis, if approved. I’m so happy for my patients and patients all around the world.”
Perhaps Dr. Nourredin will suggest a combination trial with leronlimab....
(8)
(0)
